Immutep Received ~A$1.13M R&D Tax Incentive

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or the "Company"), is pleased to announce that it has received a A$1,134,882 cash rebate from the Australian Federal Government's R&D tax

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,134,882 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2022 fiscal year, mainly related to the Company’s TACTI-002 and TACTI-003 clinical study using its lead compound eftilagimod alpha (“efti” or “IMP321”), conducted in Australia.

This follows approval from AusIndustry of Immutep’s application for an Advance/Overseas Finding. Due to the Advance Finding, both Immutep’s Australian and overseas research and development activities related to the TACTI-002 and TACTI-003 Australian sites were eligible for the R&D Tax Incentive.

Immutep also receives the French CIR tax incentive through its subsidiary Immutep S.A.S in respect of expenditure incurred on eligible R&D activities conducted in the European Union.

Immutep will apply the non-dilutive funding towards furthering its current active clinical trial programs for its lead product candidate, efti. The expected cash reach of the Company extends into early calendar year 2026.

Total
0
Shares
Related Posts
Read More

As India’s Central Bank Seeks Crypto Ban, Government Sees Need For Global Support To Regulate Bitcoin, Ethereum, And Others

India's central bank has recommended that Prime Minister Narendra Modi's government regulate or ban cryptocurrencies, but the country may need international collaboration to make a potential ban effective, the nation's Finance Minister Nirmala Sitharaman said in a written

$DOGE